Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
Gossec L., Baraliakos X., Aletaha D., Sharaf M., Rampakakis E., Lavie F., López-Medina C., Selmi C., COATES LC.